公开(公告)号：US20120198577A1

公开(公告)日：2012-08-02

申请号：US13435424

申请日：2012-03-30

Applicant: Margot Mayer-Proschel ,  Mahendra S. Rao ,  Patrick A. Tresco ,  Darin J. Messina

Inventor： Margot Mayer-Proschel ,  Mahendra S. Rao ,  Patrick A. Tresco ,  Darin J. Messina

IPC: A01K67/00 ,  A61K35/30 ,  G01N33/53 ,  C12N5/079

CPC classification number: A61K35/54 ,  A61K35/12 ,  C12N5/0623

Abstract: A method for isolating human neuroepithelial precursor cells from human fetal tissue by culturing the human fetal cells in fibroblast growth factor and chick embryo extract and immunodepleting from the cultured human fetal cells any cells expressing A2B5, NG2 and eNCAM is provided. In addition, methods for transplanting these cells into an animal are provided. Animals models transplanted with these human neuroepithelial precursor cells and methods for monitoring survival, proliferation, differentiation and migration of the cells in the animal model via detection of human specific markers are also provided.

Abstract translation: 通过培养成纤维细胞生长因子和雏鸡胚胎提取物中的人胎细胞和从培养的人胎儿细胞免疫进行分离，可以提供任何表达A2B5，NG2和eNCAM的细胞从人胎儿组织中分离人神经上皮前体细胞的方法。 另外，提供将这些细胞移植到动物体内的方法。 还提供了用这些人类神经上皮前体细胞移植的动物模型以及通过检测人特异性标志物监测动物模型中细胞的存活，增殖，分化和迁移的方法。

公开(公告)号：US20120121719A1

公开(公告)日：2012-05-17

申请号：US13265717

申请日：2009-04-22

Applicant: Patrick A. Tresco ,  Jeffrey Collins Wolchok

Inventor： Patrick A. Tresco ,  Jeffrey Collins Wolchok

IPC: A61K35/12 ,  A61P17/00 ,  A61P25/00 ,  A61P19/00 ,  A61P9/00

CPC classification number: A61L27/38 ,  A61L27/3633 ,  A61L27/56 ,  A61L2400/18 ,  C12N5/00 ,  C12N5/0068 ,  C12N2501/15 ,  C12N2527/00 ,  C12N2533/90

Abstract: Three-dimensional extracellular matrices lacking synthetic scaffolds are provided. Methods of making the three-dimensional extracellular matrices and methods of using the three-dimensional extracellular matrices are also provided.

Abstract translation: 提供缺乏合成支架的三维细胞外基质。 还提供了制备三维细胞外基质的方法和使用三维细胞外基质的方法。

公开(公告)号：US08168174B2

公开(公告)日：2012-05-01

申请号：US12395677

申请日：2009-03-01

Applicant: Margot Mayer-Proschel ,  Mahendra S. Rao ,  Patrick A. Tresco ,  Darin J. Messina

Inventor： Margot Mayer-Proschel ,  Mahendra S. Rao ,  Patrick A. Tresco ,  Darin J. Messina

IPC: C12N5/0797 ,  A61K35/30

CPC classification number: A61K35/54 ,  A61K35/12 ,  C12N5/0623

Abstract: A method for isolating human neuroepithelial precursor cells from human fetal tissue by culturing the human fetal cells in fibroblast growth factor and chick embryo extract and immunodepleting from the cultured human fetal cells any cells expressing A2B5, NG2 and eNCAM is provided. In addition, methods for transplanting these cells into an animal are provided. Animals models transplanted with these human neuroepithelial precursor cells and methods for monitoring survival, proliferation, differentiation and migration of the cells in the animal model via detection of human specific markers are also provided.

Abstract translation: 通过培养成纤维细胞生长因子和雏鸡胚胎提取物中的人胎细胞和从培养的人胎儿细胞免疫进行分离，可以提供任何表达A2B5，NG2和eNCAM的细胞从人胎儿组织中分离人神经上皮前体细胞的方法。 另外，提供将这些细胞移植到动物体内的方法。 还提供了用这些人类神经上皮前体细胞移植的动物模型以及通过检测人特异性标志物监测动物模型中细胞的存活，增殖，分化和迁移的方法。

公开(公告)号：US5955095A

公开(公告)日：1999-09-21

申请号：US436281

申请日：1995-08-14

Applicant: Frank T. Gentile ,  Tyrone Hazlett ,  Patrick A. Tresco ,  Thomas Flanagan ,  Edward J. Doherty ,  David Rein ,  Laura M. Holland

Inventor： Frank T. Gentile ,  Tyrone Hazlett ,  Patrick A. Tresco ,  Thomas Flanagan ,  Edward J. Doherty ,  David Rein ,  Laura M. Holland

IPC: A61K9/48 ,  A61F13/00

CPC classification number: A61K9/4816

Abstract: Microporous macrocapsules are disclosed which are useful as implantation devices for cell therapy. The macrocapsule comprises living cells that secrete biological substance that are therapeutically useful and that are released from the macrocapsule to the site of implantation. The capsules can have selected permeability characteristics based upon their particular usage and desired viral retentivity characteristics.

Abstract translation: PCT No.PCT / US93 / 11232 Sec。 371日期1995年8月14日 102（e）日期1995年8月14日PCT提交1993年11月16日PCT公布。 公开号WO94 / 10950 PCT 日期1994年5月26日公开了可用作细胞治疗的植入装置的大孔微胶囊。 所述大囊包含分泌生物物质的活细胞，所述活细胞在治疗上有用并从所述宏胶囊释放到植入部位。 胶囊可以根据其特定用途和期望的病毒保持性特征具有选择的渗透性特征。

公开(公告)号：US5573528A

公开(公告)日：1996-11-12

申请号：US461301

申请日：1995-06-05

Applicant: Patrick Aebischer ,  Patrick A. Tresco

Inventor： Patrick Aebischer ,  Patrick A. Tresco

IPC: A61M31/00 ,  A61F2/02 ,  A61K9/00 ,  A61K9/22 ,  A61K31/195 ,  A61K35/12 ,  A61K35/39 ,  A61K35/54 ,  A61M37/00 ,  B01J13/02 ,  C12N5/00 ,  C12N5/071 ,  C12N5/0793 ,  C12N11/04

CPC classification number: A61F2/022 ,  A61K31/14 ,  A61K31/195 ,  A61K35/39 ,  A61K35/54 ,  A61K45/06 ,  A61K9/0024 ,  A61K9/0085 ,  A61K9/0092 ,  A61M31/002 ,  B01J13/02 ,  C12N11/04 ,  C12N5/0012 ,  C12N5/0614 ,  C12N5/0619 ,  C12N5/0676 ,  A61K2035/126 ,  A61M2210/0687 ,  A61M2210/0693 ,  C12N2533/30

Abstract: Methods are disclosed for the alleviation of movement disorders via the implantation of static devices which focally release neuroinhibitory compounds to preselected brain areas. Pathological conditions to be treated by these methods include parkinsonian movement disorders, Huntington's chorea, and epileptiform seizure activity. In the treatment of parkinsonism, target areas implantation include the subthalamic nucleus, the globus pallidus internus, and the substantia nigra pars reticulata. In the treatment of epilepsy, implants may be placed in an epileptogenic focus area of neural over-activity. The devices may be polymeric implants that release neuroinhibitory compounds such as GABA, GABA agonists, GABA potentiators, action potential blockers and voltage dependent calcium channel blockers, and glutamate antagonists. Alternatively, the devices may contain living cells which secrete neuroinhibitory compounds.

公开(公告)号：US5474547A

公开(公告)日：1995-12-12

申请号：US168858

申请日：1993-12-16

Applicant: Patrick Aebischer ,  Patrick A. Tresco

Inventor： Patrick Aebischer ,  Patrick A. Tresco

IPC: A61M31/00 ,  A61F2/02 ,  A61K9/00 ,  A61K9/22 ,  A61K31/195 ,  A61K35/12 ,  A61K35/39 ,  A61K35/54 ,  A61M37/00 ,  B01J13/02 ,  C12N5/00 ,  C12N5/071 ,  C12N5/0793 ,  C12N11/04

CPC classification number: A61F2/022 ,  A61K31/14 ,  A61K31/195 ,  A61K35/39 ,  A61K35/54 ,  A61K45/06 ,  A61K9/0024 ,  A61K9/0085 ,  A61K9/0092 ,  A61M31/002 ,  B01J13/02 ,  C12N11/04 ,  C12N5/0012 ,  C12N5/0614 ,  C12N5/0619 ,  C12N5/0676 ,  A61K2035/126 ,  A61M2210/0687 ,  A61M2210/0693 ,  C12N2533/30

Abstract: Methods are disclosed for the alleviation of movement disorders via the implantation of static devices which focally release neuroinhibitory compounds to preselected brain areas. Pathological conditions to be treated by these methods include parkinsonian movement disorders, Huntington's chorea, and epileptiform seizure activity. In the treatment of parkinsonism, target areas implantation include the subthalamic nucleus, the globus pallidus internus, and the substantia nigra pars reticulata. In the treatment of epilepsy, implants may be placed in an epileptogenic focus area of neural over-activity. The devices may be polymeric implants that release neuroinhibitory compounds such as GABA, GABA agonists, GABA potentiators, action potential blockers and voltage dependent calcium channel blockers, and glutamate antagonists. Alternatively, the devices may contain living cells which secrete neuroinhibitory compounds.

Abstract translation: 公开了通过植入将脑神经抑制化合物向预选脑区域释放的静态装置来减轻运动障碍的方法。 通过这些方法治疗的病理状况包括帕金森病运动障碍，亨廷顿舞蹈病和癫痫发作活动。 在治疗帕金森综合征时，目标区域植入包括丘脑底核，苍白球和黑质黑质。 在癫痫治疗中，植入物可能被置于神经过度活动的癫痫发生重点领域。 该装置可以是释放神经抑制性化合物如GABA，GABA激动剂，GABA增效剂，动作电位阻断剂和电压依赖性钙通道阻滞剂以及谷氨酸拮抗剂的聚合物植入物。 或者，装置可以含有分泌神经抑制性化合物的活细胞。

公开(公告)号：US20140114436A1

公开(公告)日：2014-04-24

申请号：US14000008

申请日：2012-02-17

Applicant: Patrick A. Tresco ,  Michael J. Bridge

Inventor： Patrick A. Tresco ,  Michael J. Bridge

IPC: A61L27/52

CPC classification number: A61L27/52 ,  A61F5/0013 ,  A61L27/34 ,  A61L31/10 ,  A61L31/145 ,  A61N1/375 ,  Y10T156/10 ,  C08L5/04

Abstract: A medical device configured to be at least partially implanted within a host. The medical device includes an outer surface at least a portion of which is impermeable to cells but is permeable to molecules secreted by cells, the outer surface separating a space inside the medical device from a surrounding tissue of the host. The medical device also includes a diffusion sink positioned within the space and configured to cause molecules that are secreted into the tissue by immune cells during a foreign body response (FBR) to diffuse, through random motion, through the portion and into the diffusion sink.

Abstract translation: 构造成至少部分地植入主机内的医疗装置。 医疗装置包括外表面，其至少一部分对于细胞不可渗透，但对细胞分泌的分子是可渗透的，外表面将医疗装置内部的空间与宿主的周围组织分开。 医疗装置还包括位于该空间内的扩散宿，并且被配置为使得在异物反应（FBR）期间由免疫细胞分泌到组织中的分子通过随机运动扩散通过该部分并进入扩散槽。

公开(公告)号：US20090162330A1

公开(公告)日：2009-06-25

申请号：US12395677

申请日：2009-03-01

Applicant: Margot Mayer-Proschel ,  Mahendra S. Rao ,  Patrick A. Tresco ,  Darin J. Messina

Inventor： Margot Mayer-Proschel ,  Mahendra S. Rao ,  Patrick A. Tresco ,  Darin J. Messina

IPC: A61K45/00 ,  G01N33/53 ,  A61P25/28

CPC classification number: A61K35/54 ,  A61K35/12 ,  C12N5/0623

Abstract: A method for isolating human neuroepithelial precursor cells from human fetal tissue by culturing the human fetal cells in fibroblast growth factor and chick embryo extract and immunodepleting from the cultured human fetal cells any cells expressing A2B5, NG2 and eNCAM is provided. In addition, methods for transplanting these cells into an animal are provided. Animals models transplanted with these human neuroepithelial precursor cells and methods for monitoring survival, proliferation, differentiation and migration of the cells in the animal model via detection of human specific markers are also provided.

Abstract translation: 通过培养成纤维细胞生长因子和雏鸡胚胎提取物中的人胎细胞和从培养的人胎儿细胞免疫进行分离，可以提供任何表达A2B5，NG2和eNCAM的细胞从人胎儿组织中分离人神经上皮前体细胞的方法。 另外，提供将这些细胞移植到动物体内的方法。 还提供了用这些人类神经上皮前体细胞移植的动物模型以及通过检测人特异性标志物监测动物模型中细胞的存活，增殖，分化和迁移的方法。

公开(公告)号：US06284503B1

公开(公告)日：2001-09-04

申请号：US08784203

申请日：1997-01-15

Applicant: Karin D. Caldwell ,  Patrick A. Tresco ,  Jennifer Neff

Inventor： Karin D. Caldwell ,  Patrick A. Tresco ,  Jennifer Neff

IPC: C12N1108

CPC classification number: C12N7/00 ,  C07C281/02 ,  C07K1/1077 ,  C08G65/329 ,  C12N5/0068 ,  C12N2533/30 ,  C12N2533/50 ,  C12N2533/52 ,  C12N2740/16051 ,  G01N33/54353 ,  Y10S436/811 ,  Y10S436/823 ,  Y10S530/816

Abstract: The present invention is directed to a composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces and hydrophobic coated surfaces. The composition is a biomolecule conjugated end-group activated polymer (FGAP). The biomolecule conjugated EGAP can be put to numerous uses including cell adhesion, cell growth, cell sorting, and other biological assays.

Abstract translation: 本发明涉及用于调节细胞和生物分子对疏水性表面和疏水性涂覆表面的粘附性的组合物和方法。 该组合物是生物分子共轭的端基活化聚合物（FGAP）。 结合EGAP的生物分子可以被广泛使用，包括细胞粘附，细胞生长，细胞分选和其他生物测定。

公开(公告)号：US5418154A

公开(公告)日：1995-05-23

申请号：US997770

申请日：1992-12-24

Applicant: Patrick Aebischer ,  John F. Mills ,  Lars Wahlberg ,  Edward J. Doherty ,  Patrick A. Tresco

Inventor： Patrick Aebischer ,  John F. Mills ,  Lars Wahlberg ,  Edward J. Doherty ,  Patrick A. Tresco

IPC: A61F2/02 ,  A61J3/07 ,  A61K9/00 ,  A61K9/48 ,  A61K9/50 ,  A61K35/12 ,  A61K35/22 ,  A61K35/30 ,  A61M31/00 ,  B01J13/02 ,  B01J13/04 ,  C12N5/00 ,  C12N5/071 ,  C12N5/0793 ,  C12N11/04 ,  C12N11/08

CPC classification number: A61K9/0092 ,  A61F2/022 ,  A61J3/07 ,  A61K35/22 ,  A61K35/30 ,  A61K9/0024 ,  A61K9/0085 ,  A61K9/4816 ,  A61K9/4833 ,  A61K9/5089 ,  A61M31/002 ,  B01J13/02 ,  B01J13/04 ,  C12N11/04 ,  C12N11/08 ,  C12N5/0012 ,  C12N5/0614 ,  C12N5/0619 ,  A61M2210/0687 ,  A61M2210/0693 ,  C12N2533/30 ,  Y10S530/817

Abstract: Elongated seamless capsules containing biological material are prepared by a method in which a coagulant, which includes a cell suspension or other biologically active factor, and a polymeric casting solution are extruded through a common extrusion port having at least two concentric bores, such that the coagulant is extruded through the inner bore and the polymeric casting solution is extruded through the outer bore. The method involves initiating extrusion of the coagulant subsequent to initiating delivery of the casting solution through the respective bores to form a capsule having a curved and smooth leading edge shape. Delivery of the coagulant is then shut off, and extrusion of the casting solution is terminated either immediately or after some predetermined time.

Abstract translation: 包含生物材料的细长无缝胶囊通过以下方法制备，其中包括细胞悬浮液或其它生物活性因子的凝结剂和聚合物浇铸溶液通过具有至少两个同心孔的共同挤出口挤出，使得凝结剂 通过内孔挤出，并且聚合物浇铸溶液通过外孔挤出。 该方法包括在引发浇铸溶液通过相应的孔之后引发凝结剂的挤出，以形成具有弯曲且光滑的前缘形状的胶囊。 然后关闭凝结剂的输送，并且立即或在一些预定时间之后终止浇注溶液的挤出。